ViatrisHAM:VIA +0.06%60 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 685 Drug Manufacturers companies, Viatris ranks worse than 97.23% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Viatris's
Operating Income
for the
three
months ended in Mar. 2026 was €-17 Mil. Viatris's Interest Expense for the
three
months ended in Mar. 2026 was €-104 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Viatris's Interest Coverage or its related term are showing as below:
HAM:VIA'
s Interest Coverage Range Over the Past 10 Years
Min: 0.51 Med: 1.58 Max: 3.02
Current: 0.51
HAM:VIA's Interest Coverage is ranked worse than 97.23% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs HAM:VIA: 0.51
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Viatris Interest Coverage Related Terms
Viatris Interest Coverage Historical Data
* Premium members only.
The historical data trend for Viatris's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HAM:VIA vs NBIX, UTHR, ELAN: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Viatris's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Viatris did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Viatris (HAM:VIA) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viatris and its competitors. Over the past decade, Viatris' Interest Coverage has ranged from 0.51 to 3.02. According to the industry distribution chart, Viatris ranks #666 out of 685 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Viatris' Interest Coverage too high?
Viatris' current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 3.02. Based on the distribution chart, Viatris ranks #666 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Interest Coverage compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #666 out of 685 companies for Interest Coverage. This places Viatris in the lower half of its industry. The industry median Interest Coverage is 12.78. Historically, Viatris' own Interest Coverage has ranged from 0.51 to 3.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.26 — trading 48.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 48.3% above its estimated GF Value™ of €9.62.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Interest Coverage: 0 (At Loss)
GF Value™: €9.62 vs. price of €14.26 (48.3% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
